Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors

Next Previous
Trial Profile

A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs LY 3321367 (Primary) ; LY 3300054
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly

    • Most Recent Events

    • 29 Oct 2018 Planned number of patients changed from 172 to 196.
    • 20 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 07 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top